Advertisement

Topics

Clarus Re-submits Jatenzo NDA Following Positive Results of inTUne Trial

23:06 EDT 25 Jun 2017 | Drugs.com

NORTHBROOK, Ill – June 26, 2017 -- Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for Jatenzo™ (formerly Rextoro™), the Company's oral testosterone (T) replacement product for the treatment of...

Original Article: Clarus Re-submits Jatenzo NDA Following Positive Results of inTUne Trial

NEXT ARTICLE

More From BioPortfolio on "Clarus Re-submits Jatenzo NDA Following Positive Results of inTUne Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...